Atopic Dermatitis Clinical Trials Market Size & Share 2024 – 2032

Atopic Dermatitis Clinical Trials Market Size

Atopic Dermatitis Clinical Trials Market size was valued at USD 2.4 billion in 2023 and will exhibit growth at 11.4% to reach USD 6.4 billion by 2032. Rising prevalence of atopic dermatitis is a major factor accelerating the growth of this market.

For instance, as per the Global Report on atopic dermatitis 2022, the prevalence of atopic dermatitis is high, affecting up to 20% of children and up to 10% of adults. The global burden of atopic dermatitis ranks 15th among non-fatal diseases and holds the top position for skin-related conditions when measured by disability-adjusted life years. Thus, with such increasing prevalence of atopic dermatitis, investments in research and development activities are growing, thereby accelerating the atopic dermatitis clinical trials market growth.
 

Atopic dermatitis, often referred to as eczema, is a chronic skin condition characterized by inflammation and itching. It commonly appears as dry, red, and itchy patches on the skin, which can sometimes ooze or crust over. Clinical trials for atopic dermatitis (AD) are essential for developing and evaluating new treatments and therapies aimed at managing the symptoms of this chronic skin condition. These trials typically follow a structured process and involve various phases to assess safety, efficacy, and tolerability.
 

Atopic Dermatitis Clinical Trials Market Trends

• The rising incidence and prevalence rates of atopic dermatitis worldwide drive the demand for clinical trials to develop effective treatments to address the growing burden of the disease. For instance, as per the Global Burden of Disease (GBD 2022), about 223 million people were affected with atopic dermatitis, of which around 43 million are aged 1 to 4.
   
• Such increasing number of patients necessitate the development of effective therapies, thereby fostering the growth of market.
   
• Furthermore, increased awareness of the socioeconomic burden of atopic dermatitis prompts heightened investment from pharmaceutical companies, biotechnology firms, government agencies, and venture capital investors in research and development activities and clinical trials.
   
• Moreover, the expanding pipeline of treatments for atopic dermatitis is a key driving force in the clinical trials market due to the increasing number of clinical trials to test these diverse therapeutic approaches, further fostering the market expansion.
   

Atopic Dermatitis Clinical Trials Market Analysis

The global market, based on molecule type is segmented into large molecules and small molecules. The large molecules segment accounted for highest business share of 54.1% in 2023.
 

• Biologics, which are large molecule drugs derived from living organisms, have shown significant efficacy in the treatment of atopic dermatitis. They target specific components of the immune system involved in the disease's pathogenesis, offering a more targeted and potent therapeutic approach compared to traditional small molecule drugs.
   
• In addition, there has been a surge in the development of biologic therapies for atopic dermatitis, with numerous monoclonal antibodies and other large molecule drugs in various stages of clinical development.
   
• Further, several biologic drugs have demonstrated promising results in clinical trials for atopic dermatitis, leading to their approval and commercialization.
   

The atopic dermatitis clinical trials market based on study design is classified into interventional study, observational study, and expanded access study. The interventional study segment is expected to grow at 11.1% over the forecast period.
 

• Interventional studies provide valuable insights into the efficacy and safety of new treatments, helping researchers and healthcare providers make informed decisions about patient care


• They also play a crucial role in advancing scientific knowledge and understanding of the underlying mechanisms of atopic dermatitis, leading to the development of more targeted and effective therapies.
   
• Furthermore, interventional studies often involve collaboration between various stakeholders, including pharmaceutical companies, academic institutions, and patient advocacy groups, fostering a multidisciplinary approach to research and innovation in the field.
   
• Moreover, the rising prevalence of atopic dermatitis worldwide has fueled the demand for clinical trials, further driving the growth of the interventional study segment.
   

Learn more about the key segments shaping this market

Download Free PDF

The atopic dermatitis clinical trials market based on phase, is segmented into phase I, phase II, phase III, and phase IV. The phase II segment was valued at USD 1.2 billion in 2023.
 

• The high segment share is primarily attributed to the growing number of drugs undergoing Phase II clinical trials. This indicates a significant level of activity and investment in this phase, leading to a larger market share.
   
• Phase 2 trials serve as a crucial stage in determining the efficacy and safety of experimental treatments for atopic dermatitis. These trials involve a larger patient population than Phase 1 trials, allowing researchers to gather more robust data on the drug's effectiveness in treating the condition while continuing to monitor safety profiles.
   

The atopic dermatitis clinical trials market, based on mode is categorized into outsourced and in-house. The outsourced segment accounted for majority of revenue share in 2023 and is expected to grow significantly to reach USD 3.9 billion by 2032.
 

• Outsourcing facilities have a global presence and access to a diverse network of clinical trial sites and investigators. This enables them to recruit patients from different geographical regions, ethnic backgrounds, and demographic profiles, thereby enhancing the diversity and representativeness of clinical trial populations.
   
• In addition to this, growing prevalence of atopic dermatitis, increased demand for novel treatment, the increasing adoption of CROs, and access to specialized expertise supports the growth of this segment.
   

The atopic dermatitis clinical trials market based on industry, is segmented into contract research organizations, pharmaceutical and biotechnology companies, and research and academic institutes. The contract research organization segment is anticipated to grow at CAGR of 12.1% up to 2032.
 

• Contract research organization is a cost-effective option for pharmaceutical and biotechnology companies, especially for smaller firms with limited internal resources. They offer scalable services, allowing sponsors to optimize resource allocation based on the specific needs and complexities of each trial.
   
• Additionally, it reduces the need for upfront investments in infrastructure, personnel, and technology, leading to cost savings and improved budget predictability.
   
• Further, CRO’s offer specialized expertise in conducting clinical trials efficiently and effectively. They have dedicated teams with experience in trial design, patient recruitment, regulatory compliance, data management, and site monitoring. Such factors are responsible for accelerating the growth of this segment.
   

North America atopic dermatitis clinical trials market accounted for USD 945.8 million revenue in 2023 and is anticipated to grow at a CAGR of 10.8% over the analysis period.
 

• The region possesses a robust research infrastructure with leading academic institutions, medical centers, and pharmaceutical companies actively involved in atopic dermatitis research.
   
• The region has a highly skilled workforce, advanced healthcare facilities, and state-of-the-art research laboratories, making it an attractive destination for conducting clinical trials.
   
• Additionally, the region has a substantial patient population affected by atopic dermatitis, contributing to a high demand for clinical trials in the region.
   
• Moreover, factors such as favorable regulatory environment, access to funding, collaborative networks, and strong market demand contribute to the continuous growth of North America market.
   

Atopic Dermatitis Clinical Trials Market Share

The atopic dermatitis clinical trials industry is dynamic and multifaceted, characterized by the presence of various stakeholders including pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic institutions. Trials often focus on efficacy, safety, and long-term effects, seeking to enhance patient outcomes and quality of life. Collaboration between researchers, healthcare institutions, and pharmaceutical entities drives progress in this dynamic field.
 

Atopic Dermatitis Clinical Trials Market Companies

Prominent players operating in the atopic dermatitis clinical trials industry include:

• BIOCYTOGEN
• Charles River Laboratories
• Hooke Laboratories, LLC
• Imavita
• Novotech
• Oncodesign services
• QIMA LTD
• Redoxis
• REPROCELL Inc.
• Syneos Health
   

Atopic Dermatitis Clinical Trials Industry News:

• In October 2023, LEO Pharma announced the positive outcome of the DELTA 3 trial. DELTA 3, a Phase 3 extension trial, evaluated delgocitinib cream, an investigational topical pan-Janus kinase (JAK) inhibitor, for potential treatment in adults with moderate to severe chronic hand eczema (CHE). This positive result enhanced the value of the company’s pipeline and will help in commercializing the product.
   
• In May 2023, Dermavant Sciences, Inc. announced positive results from ADORING 1, Phase 3 studies evaluating the efficacy and safety of topical VTAMA (tapinarof) cream 1% in adults and pediatric subjects as young as 2 years old with moderate to severe atopic dermatitis. It provided the company with a pathway to commercial success, market expansion, competitive differentiation, and investor support.
   

The atopic dermatitis clinical trials market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Molecule Type

• Large molecules
• Small molecules

Market, By Study Design

• Interventional study
• Observational study
• Expanded access study

Market, By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

Market, By Mode

• Outsourced
• In-house

Market, By Industry

• Contract research organizations
• Pharmaceutical and biotechnology companies
• Research and academic institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa